New York (ots/PRNewswire) - Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S -- the largest pharmaceutical wholesaler in Denmark -- that prohibits the sale of a generic version of Lipitor by generics manufacturer Ranbaxy. The injunction, issued by the Bailiff's Court of the Copenhagen City Court in Denmark and ...
New York (ots/PRNewswire) - - Celebrex to be Available in Europe for the Treatment of Ankylosing Spondylitis, a Debilitating Form of Arthritis Pfizer Inc announced today that 17 European countries agreed to extend the Celebrex (celecoxib capsules) label to include symptomatic relief in the treatment of ankylosing spondylitis (in adults), a form of arthritis that affects the spine. Once each country updates ...
Irvine, California (ots/PRNewswire) - - Update on Recent Events IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today reported preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2006. Revenue was approximately US$10 million (unaudited) for the fourth quarter of 2006, representing a 16% increase over revenue of the fourth quarter of 2005. For the full year 2006, ...
Lyon, France (ots/PRNewswire) - - New Vaccine Will Help Improve Public Health in Japanese Encephalitis Endemic Countries Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today it has entered into an agreement with Acambis plc to license a single dose vaccine against Japanese encephalitis (JE), ChimeriVaxTM-JE, to help improve ...
New York (ots/PRNewswire) - - If Approved, Maraviroc will be the First in a New Class of Medications Available for HIV Treatment Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would ...
Basel (ots/PRNewswire) - - First Worldwide Test of Public's Knowledge About Kidneys On-line Quiz Launches Today Our kidneys are amazing organs that play a crucial role in keeping us alive and well - but how much do we really know about them and do we know what can happen if disease sets in? This is the ...
Abbott Park, Illinois (ots/PRNewswire) - - First-of-its-Kind Study Designed to Learn More About Cardiovascular Disease in Women Abbott today announced plans to initiate the world's first drug-eluting stent clinical trial solely in women. The SPIRIT WOMEN trial will aim to increase understanding of how ...
Ingelheim, Germany (ots/PRNewswire) - Long-term data from the Nevirapine/Efavirenz/Abacavir (NEFA) study demonstrate that patients who switched from a protease inhibitor-based regimen to a non-nucleoside reverse transcriptase inhibitor-based regimen containing Viramune(R) (nevirapine) or efavirenz achieved comparable efficacy and safety to their previous regimen ...
Vancouver, Canada (ots/PRNewswire) - Perceptronix Medical Inc. ("Perceptronix") today announced its participation in a research project to detect early oral cancer lesions through a new initiative inside the BC Oral Cancer Prevention Program. This Program is bringing together a network of dentists, researchers and technology companies to develop early screening ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 22.01.2007 Pfaeffikon SZ, 22 January 2007 --- The Board of Directors of shaPE Capital AG today announced that within the limits of the capital increase all subscription rights have been ...
Basel, Switzerland (ots/PRNewswire) - - New Phase III Data Presented at the American Society of Clinical Oncology Gastrointestinal Symposium (ASCO GI) continue to demonstrate the excellent efficacy of two of Roche's innovative cancer drugs Xeloda and Avastin, which offer improved survival for patients ...
Vancouver, Canada (ots/PRNewswire) - Perceptronix CEO Carl Roy announced the appointment of Ms. Rohini Hira to the position of Vice President Sales and Marketing effective December 15th, 2006. Ms. Hira has the vision and experience to commercialize Perceptronix' early cancer detection products and services in Canada, the US and the EU. Ms. Hira's career spans ...
New York (ots/PRNewswire) - - Full marketing authorization and extension of indication to first-line treatment of advanced and/or metastatic renal cell carcinoma (MRCC) - First multiple receptor tyrosine kinase inhibitor to be approved in the EU for first-line use in MRCC Pfizer Inc said today that ...
Philadelphia, Pennsylvania (ots/PRNewswire) - - Study to Compare Immunogencity of GSK's Cervical Cancer Candidate Vaccine, CERVARIX(R), to Merck's Gardasil(R) GlaxoSmithKline (NYSE: GSK) announced today the initiation of the first study of its kind designed to compare the immunogenicity of its cervical cancer candidate vaccine, CERVARIX(R), versus ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that its partner, Lux Biosciences, has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for ISA247, referred to as LX211 by Lux, for the treatment of non-infectious posterior, intermediate and ...
Pompey, France (ots/PRNewswire) - Groupe Novasep has been acquired for an enterprise value of EUR 425 million by its management and by a financial investor group composed of Gilde Buy Out, Banexi Capital Partenaires, BNP Paribas. The acquisition has been signed on November 29th, 2006 and completed on January 9th ...
Calgary, Alberta (ots/PRNewswire) - - Canadian Biotechnology Company Takes Next Significant Step Towards Advancing its Product to the Clinic - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical products, today ...
Alderley Park, England (ots/PRNewswire) - - For Non-US Healthcare Press Only AstraZeneca today announced RECENTIN(TM) as the global trademark for AZD2171, its oral, highly potent and selective vascular endothelial growth factor (VEGF) signalling inhibitor. AZD2171 is currently in Phase II/III development for advanced non-small cell lung cancer (NSCLC) and ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 04.01.2007 Pfaeffikon SZ, 4 January 2007 --- The Board of Directors of shaPE Capital AG decided today to increase the share capital by issuance of up to 228667 registered shares with a par ...
Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company Shortens Clinical Timelines by Eliminating Duplicative Insulin Trials TSX symbol: SBS SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical ...
New York (ots/PRNewswire) - Xenomics, Inc. (the "Company") (OTC Bulletin Board: XNOM; FWB: XE7), source of next-generation medical DNA technologies, announced today the closing of a private placement totaling US$1.0 million, whose proceeds will help to fund the Company's efforts to develop advanced medical diagnostic tests for a range of diseases and genetic conditions, and to fund preparations toward product ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - - Record Production Capabilities Strengthen sanofi pasteur's Global Leadership in the Fight Against Seasonal Influenza and Place the Company at the Forefront of Pandemic Readiness sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY; EURONEXT: SAN), announced that it ...
Basel, Switzerland (ots/PRNewswire) - Today's positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) of Tibotec's boosted protease inhibitor darunavir is good news for HIV treatment-experienced patients facing drug resistance. Studies have shown that darunavir, when used in ...
Pompey, France (ots/PRNewswire) - Solvay Pharmaceuticals and Novasep have signed a five-year strategic manufacturing alliance which includes the exclusive synthesis of two active pharmaceutical ingredients for Solvay Pharmaceuticals. Solvay and Novasep have recently set a strategic manufacturing alliance defining Novasep as a preferred partner for the ...
Amsterdam, The Netherlands (ots/PRNewswire) - - In Germany, 80 Million Patient Cards Will be Renewed Over the Next 5 Years Gemalto (Euronext NL0000400653 GTO), a world leader in digital security, today announces it is taking part in Germany's first healthcare pilot program based on highly secure microprocessor cards. The Gemalto product is fully compliant ...
Basel, Switzerland (ots/PRNewswire) - - Avastin is First Medicine to Extend Survival Beyond One Year in Patients With Previously Untreated Non-Small Cell Lung Cancer Avastin is the first medicine proven to help previously untreated patients suffering from the most common form of lung cancer to live longer than a year, according to a landmark US study ...
Orlando, Florida (ots/PRNewswire) - - The PREVAIL Study Showed That in Acute Ischemic Stroke Patients Treated With Clexane(R) / Lovenox(R), the Risk of Having a VTE was Lowered by a Significant 43% With no Significant Increase in Clinically Important Bleedings When Compared to UFH Sanofi-aventis announced ...
Paris (ots/PRNewswire) - - New Data Presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) For Non-US Journalists Only New data presented today showed that a substantial number of patients with chronic-phase chronic myelogenous leukaemia (CML) resistant to ...
Basel, Switzerland (ots/PRNewswire) - - Roche to Approach World-Wide Regulatory Authorities for a New File Submission Roche announced today that a large, international Phase III study (NO16967) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival. Study results showed that the chemotherapy ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 07.12.2006 Pfaeffikon SZ, 7 December 2006 --- shaPE Capital AG today announced an extra-ordinary general meeting which will take place on 4 January 2007 to create an authorized share capital. ...